Summary
This external evaluation was carried out by the Centre for Strategy & Evaluation Services (CSES) for DG Justice of the European Commission. The exercise began in September 2011 and was concluded in June 2012.
The evaluation examined:
- How the conclusions and recommendations of the previous 2007 evaluation of the EMCDDA and the Reitox focal points were taken into account and the extent to which their implementation has improved the overall performance of the EMCDDA;
- The relevance, effectiveness, coherence, efficiency and impact of the activities carried out by the EMCDDA under its two three-year work programmes 2007–09 and 2010–12 (outputs and effects until July 2011) in the context of the mandate and priorities given to the EMCDDA in its Regulation (1920/2006);
- The relevance, effectiveness, coherence, efficiency, utility and added value of the Reitox network and its contribution to the achievements of the EMCDDA’s outputs during the evaluation period;
- How outputs and effects from the EMCDDA work programmes during the evaluation period have contributed to the EU drugs strategy 2005–12 and the EU drugs action plans 2005–08 and 2009–12.
Download as PDF
EMCDDA-evaluation-2012-main-report
PDF files are made available as a convenience. In cases where the EMCDDA is not the originator of the document, please be aware that any PDFs available on this page may not be authoritative or there may be more recent versions available. While we make every effort to ensure that these files are definitive, before using or citing them, we recommend that you consult the publisher's website or contact the author(s) to check for more recent versions.